Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Examination of Micro Vascular Density on Metastatic Colorectal Cancer of RAS Mutant-Type as Anti Vegf Therapy Predictor

Folia Medica Indonesiana · Vol. 57 No. 2 (2021) · hlm. 111–111

DOI
10.20473/fmi.v57i2.18249
ISSN
2355-8393, 2599-056X
Terbit
2021-06-01
Penerbit
Airlangga University
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0/

Abstrak

According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Colon Cancer Version 2.2019, mCRC patients with mutant type RAS were treated with anti-VEGF. However, the use of the targeting therapy still had inconsistent results. Neoangiogenesis studies had been used as a basis to assess the prognosis of mCRC. Microvascular density (MVD) had become the morphological gold standard to assess neovascularization in human tumors. This study proved the existence of low microvascular density (MVD) in mCRC patients with mutant type RAS status as a predictor of failure of anti-VEGF therapy. There were 29 patients at Dr. Soetomo Academic Hospital from 2015-2018 who had their RAS status checked and tested for microvascular density (MVD). The results of this study were analyzed using SPSS 23.0. In the Mutant-type of RAS group, this study examined microvascular density (MVD). 11 (73%) research subjects with high MVD scores and 4 (27%) research subjects had low MVD scores. Besides, 27% microvascular density (MVD) was low, in the mutant-type of RAS mCRC patient which could be a predictor factor for the failure of anti-VEGF therapy.

Kata kunci

Jaringan kolaborasi para penulis

7 penulis · 16 tautan kepenulisan bersama · 9 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • Universitas Katolik Widya Mandala Surabaya
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
I Ketut SudianaUniversitas Airlangga1
Bernadette Dian NovitaUniversitas Katolik Widya Mandala Surabaya1
Sianty DewiUniversitas Katolik Widya Mandala Surabaya1
Imelda TheodoraUniversitas Airlangga1
Ferdinand ErwinUniversitas Katolik Widya Mandala Surabaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Examination of Micro Vascular Density on Metastatic Colorectal Cancer of RAS Mutant-Type as Anti Vegf Therapy Predictor</dc:title><dc:creator>Heru Sulistyo</dc:creator><dc:creator>Vicky Sumarki Budipramana</dc:creator><dc:subject>metastatic colorectal cancer</dc:subject><dc:subject>RAS mutations</dc:subject><dc:subject>microvessel density</dc:subject><dc:subject>anti-VEGF therapy</dc:subject><dc:subject>treatment failure prediction</dc:subject><dc:subject>tumor angiogenesis</dc:subject><dc:subject>neovascularization</dc:subject><dc:subject>prognostic factors</dc:subject><dc:description xml:lang="en">According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Colon Cancer Version 2.2019, mCRC patients with mutant type RAS were treated with anti-VEGF. However, the use of the targeting therapy still had inconsistent results. Neoangiogenesis studies had been used as a basis to assess the prognosis of mCRC. Microvascular density (MVD) had become the morphological gold standard to assess neovascularization in human tumors. This study proved the existence of low microvascular density (MVD) in mCRC patients with mutant type RAS status as a predictor of failure of anti-VEGF therapy. There were 29 patients at Dr. Soetomo Academic Hospital from 2015-2018 who had their RAS status checked and tested for microvascular density (MVD). The results of this study were analyzed using SPSS 23.0. In the Mutant-type of RAS group, this study examined microvascular density (MVD). 11 (73%) research subjects with high MVD scores and 4 (27%) research subjects had low MVD scores. Besides, 27% microvascular density (MVD) was low, in the mutant-type of RAS mCRC patient which could be a predictor factor for the failure of anti-VEGF therapy.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2021-06-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v57i2.18249</dc:identifier><dc:identifier>10.20473/fmi.v57i2.18249</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 57 No 2 (2021); 111-111</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/18249/14930</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>